 Shares of conditionally active biologics concern BioAtla, Inc. are beginning to rebound from a 97 plunge as encouraging data from two candidates has sparked the turnaround. BioAtla leverages its expertise of the tumor microenvironment to develop highly selective and reversible biologics, with applications across the entire antibody-based biologic spectrum. 